# EVOKE-02 (NCT05186974)

> Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05186974
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Non-small Cell Lung Cancer
- Interventions: Sacituzumab Govitecan-hziy (SG); Pembrolizumab; Carboplatin; Cisplatin
- Enrollment: 193
- Primary outcome: Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Primary outcome: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts

## Commentary we found

- X threads: 13
- Podcasts: 11
- YouTube: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=evoke-02-nct05186974

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05186974", "email": "<work email>"}; the inbox owner confirms by the emailed link.